Rusfertide's REVIVE Study Highlights 2-Year Efficacy in Polycythemia Vera (PV)

Protagonist Therapeutics, Inc. has unveiled compelling data from its Rusfertide REVIVE study during the American Society of Hematology 2023 Annual Meeting. The study spans two years, demonstrating the lasting efficacy and safety of rusfertide, a hepcidin mimetic, in treating polycythemia vera (PV) patients. The findings showcase significant benefits, including durable hematocrit control, reduced phlebotomy needs, and overall improved patient outcomes.

Want to read more?

Subscribe to gmpnsf.org to keep reading this exclusive post.

Subscribe Now